

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number
WO 01/51466 A1

(51) International Patent Classification⁷: **C07D 209/42**,
A61K 31/404, A61P 29/00

[GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number: PCT/GB01/00069

(74) Agent: **BRYANT, Tracey**; Astrazeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (US).

(22) International Filing Date: 11 January 2001 (11.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0000626.2 13 January 2000 (13.01.2000) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertalje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

Published:


— with international search report

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FAULL, Alan, Wellington** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **KETTLE, Jason, Grant**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS**



(57) Abstract: A compound of formula (I) wherein: R¹ is hydrogen, halo or methoxy; R² is hydrogen, halo, methyl, ethyl or methoxy; R³ is a halo group or a trifluoromethyl group; R⁴ is a halo group or a trifluoromethyl group; R⁵ is hydrogen or halo; R⁶ is hydrogen or halo; provided that when R⁵ and R⁶ are both hydrogen, and one of R³ or R⁴ is chloro or fluoro, then the other is not chloro or fluoro; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonising an MCP-1 mediated effect in a warm-blooded animal such as a human being.

WO 01/51466 A1

INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS

The present invention relates to anti-inflammatory compounds that act via antagonism of the CCR2 receptor, (also known as the MCP-1 receptor), leading *inter alia* to inhibition of
5 Monocyte Chemoattractant Protein-1 (MCP-1). These compounds contain an indole moiety. The invention further relates to pharmaceutical compositions containing them, processes for their preparation, intermediates useful in their preparation and to their use as therapeutic agents.


MCP-1 is a member of the chemokine family of pro-inflammatory proteins which
10 mediate leukocyte chemotaxis and activation. MCP-1 is a C-C chemokine which is one of the most potent and selective T-cell and monocyte chemoattractant and activating agents known. MCP-1 has been implicated in the pathophysiology of a large number of inflammatory diseases including rheumatoid arthritis, glomerular nephritides, lung fibrosis, restenosis (International Patent Application WO 94/09128), alveolitis (Jones et al., 1992, *J. Immunol.*,
15 149, 2147) and asthma. Other disease areas where MCP-1 is thought to play a part in their pathology are atherosclerosis (e.g. Koch et al., 1992, *J. Clin. Invest.*, 90, 772-779), psoriasis (Deleuran et al., 1996, *J. Dermatological Science*, 13, 228-236), delayed-type hypersensitivity reactions of the skin, inflammatory bowel disease (Grimm et al., 1996, *J. Leukocyte Biol.*, 59, 804-812), multiple sclerosis and brain trauma (Berman et al, 1996,
20 *J. Immunol.*, 156, 3017-3023). An MCP-1 inhibitor may also be useful to treat stroke, reperfusion injury, ischemia, myocardial infarction and transplant rejection.

MCP-1 acts through the CCR2 receptor. MCP-2 and MCP-3 may also act, at least in part, through this receptor. Therefore in this specification, when reference is made to "inhibition or antagonism of MCP-1" or "MCP-1 mediated effects" this includes inhibition or
25 antagonism of MCP-2 and/or MCP-3 mediated effects when MCP-2 and/or MCP-3 are acting through the CCR2 receptor.

The applicants have found a class of compounds containing an indole moiety which have useful inhibitory activity against MCP-1. International Patent Application, Publication No. WO 99/07351 discloses a class of indoles with MCP-1 inhibitory activity. This
30 application is based on the surprising discovery that particular substituted 5-hydroxy indoles are MCP-1 inhibitors which possess unexpected and beneficial properties with respect to potency and/or blood levels and/or bioavailability and/or solubility.

- 2 -

Accordingly, the present invention provides a compound of the formula (I):



wherein:

- 5 R^1 is hydrogen, halo or methoxy;
 R^2 is hydrogen, halo, methyl, ethyl or methoxy;
 R^3 is a halo group or a trifluoromethyl group;
 R^4 is a halo group or a trifluoromethyl group;
 R^5 is hydrogen or halo;
 10 R^6 is hydrogen or halo;
 provided that when R^5 and R^6 are both hydrogen, and one of R^3 or R^4 is chloro or fluoro, then the other is not chloro or fluoro;
 or a pharmaceutically acceptable salt or prodrug thereof.

15 In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. The term "halo" refers to fluoro, chloro, bromo and iodo.

 Suitable examples of R^1 are hydrogen, fluoro, chloro, bromo, iodo or methoxy. Preferably R^1 is hydrogen, fluoro or chloro, and most preferably R^1 is hydrogen.

20 Particular examples of R^2 are hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl or methoxy. Suitably R^2 is hydrogen, chloro, bromo, iodo or methoxy, and preferably R^2 is hydrogen.

 In one embodiment, R^5 and R^6 are both hydrogen. In this case, when R^4 is trifluoromethyl, R^3 is suitably a chloro, fluoro, bromo or iodo group, preferably a chloro, fluoro or bromo group, and most preferably chloro or fluoro.

- 3 -


Alternatively, where R^5 and R^6 are both hydrogen, R^3 is trifluoromethyl, and R^4 is halo such as fluoro, chloro, bromo or iodo, and preferably chloro or fluoro and most preferably chloro.

Similar combinations of R^3 and R^4 may apply where at least one of R^5 and R^6 is other than hydrogen, but in this case, R^3 and R^4 are suitably both halo such as fluoro, chloro, bromo and iodo, preferably fluoro, chloro or bromo, and most preferably fluoro or chloro. Particular examples are cases where R^3 and R^4 are both chloro, or R^3 and R^4 are both fluoro. A further alternative is one in which one of R^3 or R^4 is chloro and the other is fluoro.

Suitably R^5 is hydrogen, fluoro, chloro or bromo, and preferably R^5 is hydrogen. A further preferred value for R^5 is, for example, fluoro.

Suitably R^6 is hydrogen, fluoro, chloro or bromo. Preferably R^6 is hydrogen or fluoro, and most preferably hydrogen.

In a preferred aspect of the invention there is provided a compound of formula (IA):



15

(IA)

or a pharmaceutically acceptable salt or prodrug thereof, wherein R^1 , R^2 and R^4 are as defined above. Preferably R^1 and R^2 are hydrogen. Preferably R^4 is chloro or fluoro.

In a further preferred aspect of the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof wherein R^1 , R^2 and R^4 are as defined above, R^3 is trifluoromethyl, R^5 is halo and R^6 is hydrogen. Preferably R^1 and R^2 are hydrogen. Preferably R^4 is chloro or fluoro, especially chloro. Preferably R^5 is fluoro.

Preferred compounds of the invention include any one of the compounds prepared in the Examples, which are summarised in Table 1.

Table 1

Example	R1	R2	R3	R4	R5	R6
1	H	H	CF ₃	Cl	H	H
2	H	H	F	CF ₃	H	H
3	H	H	Cl	CF ₃	H	H
4	H	H	Br	Cl	H	H
5	H	H	F	Br	H	H
6	H	H	Br	F	H	H
7	F	H	CF ₃	F	H	H
8	F	H	CF ₃	Cl	H	H
9	F	H	CF ₃	F	F	H
10	Cl	H	Cl	Cl	Cl	H
11	H	Br	CF ₃	F	H	H
12	H	Br	CF ₃	Cl	H	H
13	H	Br	Cl	CF ₃	H	H
14	H	Cl	F	CF ₃	H	H
15	H	I	F	CF ₃	H	H
16	H	CH ₃ O	CF ₃	Cl	H	H
17	H	H	CF ₃	F	Cl	H
18	H	H	CF ₃	Cl	Cl	H
19	H	H	CF ₃	Cl	H	F
20	H	H	CF ₃	Cl	Br	H
21	H	H	Cl	Cl	Br	H
22	H	H	CF ₃	Cl	F	H
23	H	H	Cl	Cl	F	H
24	H	H	Cl	Cl	Cl	H
25	Cl	H	CF ₃	Cl	H	H
26	Cl	H	CF ₃	Cl	Cl	H

The invention further relates to all tautomeric forms of the compounds of formula (I).

- 5 -

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

Compounds of formula (I) are inhibitors of monocyte chemoattractant protein-1. In addition, they appear to inhibit RANTES induced chemotaxis. RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted) is another chemokine from the same family as MCP-1, with a similar biological profile, but acting through the CCR1 receptor. Accordingly a further advantage associated with the present invention is that, by inhibition of both MCP-1 and RANTES activity, it provides compounds with particularly useful properties. As a result, these compounds can be used to treat disease mediated by these agents, in particular inflammatory disease.

Suitable pharmaceutically acceptable salts of compounds of formula (I) include base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or amino acids for example lysine. In another aspect, where the compound is sufficiently basic, suitable salts include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a sodium salt.

Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- 25 b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- 30 e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

Examples of such prodrugs are *in vivo* cleavable esters of a compound of the invention. An *in vivo* cleavable ester of a compound of the invention containing a carboxy


- group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include C₁₋₆alkyl esters, for example methyl or ethyl; C₁₋₆alkoxymethyl esters, for example methoxymethyl; C₁₋₆alkanoyloxymethyl esters, for example pivaloyloxymethyl;
- 5 phthalidyl esters; C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-ylmethyl esters, for example 5-methyl-1,3-dioxolan-2-ylmethyl; C₁₋₆alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl; aminocarbonylmethyl esters and mono- or di- N-(C₁₋₆alkyl) versions thereof, for example N,N-dimethylaminocarbonylmethyl esters and
- 10 N-ethylaminocarbonylmethyl esters; and may be formed at any carboxy group in the compounds of this invention. An *in vivo* cleavable ester of a compound of the invention containing a hydroxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent hydroxy group. Suitable pharmaceutically acceptable esters for hydroxy include C₁₋₆alkanoyl esters, for example
- 15 acetyl esters; and benzoyl esters wherein the phenyl group may be substituted with aminomethyl or N- substituted mono- or di- C₁₋₆alkyl aminomethyl, for example 4-aminomethylbenzoyl esters and 4-N,N-dimethylaminomethylbenzoyl esters.

- Further examples of such prodrugs are *in vivo* cleavable amides of a compound of the invention. Examples of such *in vivo* cleavable amides include an N-C₁₋₆alkylamide and an
- 20 N,N-di-(C₁₋₆alkyl)amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethylamide.

Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof which process comprises:


- 25 a) reacting compounds of formula (II):

- 7 -



(II)

where R^1 , R^2 , R^5 and R^6 are as defined in relation to formula (I), R^a is carboxy or a protected form thereof, and R^b is hydrogen or a suitable hydroxy protecting group, with a compound of
 5 formula (III):



(III)

where R^3 and R^4 are as defined in relation to formula (I) and L is a displaceable group; and thereafter if necessary:

- 10 i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or prodrug thereof.


Suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

- 15 Compounds of formula (II) and (III) are suitably reacted together in an inert organic solvent such as *N,N*-dimethylformamide, dichloromethane or acetonitrile in the presence of a base such as sodium hydroxide, sodium hydride or potassium carbonate. Suitably the reaction is effected in the presence of a phase transfer catalyst such as tetra-*n*-butylammonium hydrogensulphate. Reaction times may range for 1-6 hours preferably for 1-3 hours.

- 20 Moderate temperatures for example of 15-30°C, preferably 20-25°C are employed.


Compounds of formula (II) may be commercially available, or they may be made by modification using known processes of commercially available compounds of formula (II). In particular, they may be prepared by reacting a compound of formula (IV):

- 8 -



(IV)

where R^1 , R^5 , R^6 and R^b is as defined above with a compound of formula (V)




(V)

where R^c and $R^{c'}$ are independently selected from C_{1-4} alkyl.

Compounds of formula (IV) and (V) are suitably reacted together under Reissert reaction conditions such as in an inert solvent (such as tetrahydrofuran), in the presence of a base (such as potassium ethoxide), at a temperature range of 15-30 °C preferably 20-25 °C, for 10-20 hours preferably 15-17 hours. The resulting compound is isolated and dissolved in an alcohol such as ethanol and an organic acid (such as acetic acid) and a transition metal catalyst (such as 10% Pd/C) and cyclohexene is added. The mixture may then be heated at a temperature of 60-120 °C preferably at 70-90 °C for 15-25 hours preferably 16-20 hours to give a compound of formula (II) wherein R^a is $-CO_2R^c$.

R^c and $R^{c'}$ are suitably C_{1-4} alkyl, preferably methyl or ethyl.


Alternatively, compounds of formula (II) can be prepared by reacting a compound of formula (VI):



(VI)

where R^1 , R^5 , R^6 and R^b are as defined above, with a compound of formula (VII):

- 9 -




(VII)

where R^d is C_{1-4} alkyl.

Suitably R^d is C_{1-4} alkyl, preferably methyl or ethyl.

- 5 Compounds of formula (VI) and (VII) are suitably reacted together under Fischer conditions such as with an organic acid (such as acetic acid), in an alcohol (such as ethanol), at a temperature of 60-90°C, preferably 75-85°C, for 1-5 hours, preferably 1-3 hours. The resulting compound is mixed with a strong acid (such as polyphosphoric acid) and heated at 90-150°C preferably 100-120°C, for 0.5-4 hours, preferably 0.5-2 hours to give a compound
- 10 of formula (II) in which R^2 is hydrogen. Then, if desired, R^2 can be optionally converted into another value of R^2 as defined in formula (I) using techniques known in the literature.


In a preferred alternative, compounds of formula (II) are obtained by cyclisation of a compound of formula (VIII)



(VIII)

where R^1 , R^a , R^b and R^2 are as defined above.


- Cyclisation may be effected by refluxing the compound in an organic solvent such as xylene. Compounds of formula (VIII) are suitably prepared by reacting a compound of
- 20 formula (IX)



(IX)


- 10 -

where R^1 , R^2 and R^b are as defined above, with a compound of formula (X)



5 where R^a is as defined above. The reaction is suitably effected in an organic solvent such as an alcohol, in particular methanol, in the presence of a base such as an alkali metal alkoxide, in particular sodium methoxide. Moderate temperatures of from -30 to 20°C are suitably employed.


In yet a further modification, compounds of formula (II) are prepared by cyclisation of
10 a compound of formula (XI)



where R^1 and R^b are as defined above, R^7 is alkyl, such as methyl, and R^8 is a carboxy
15 protecting group such as alkyl, in particular methyl.


Cyclisation is suitably effected under Japp Klingemann conditions, by warming a solution of the compound in an organic solvent such as toluene and a suitable acid, such as p-toluene sulphonic acid.

Compounds of formula (XI) are suitably prepared by reacting a compound of formula
20 (XII)



- 11 -

where R^1 , R^b , R^5 and R^6 are as defined above, with a compound of formula (XIII)



(XIII)

5 where R^7 and R^8 are as defined in relation to formula (XI). The compound of formula (XII) is suitably dissolved in a dilute acid such as 1.5N HCl in the presence of a nitrite such as sodium nitrite at moderately low temperatures from -30 to 0°C, preferably -5°C.

This solution is then mixed with a solution of a compound of formula (XIII) in an organic solvent such as ethanol, in the presence of a solution of a base such as an alkali metal
10 hydroxide, for example aqueous sodium hydroxide solution.

Compounds of formula (III), (IV), (V), (VI), (VII), (IX), (X) and (XII) are known or commercially available or are prepared by processes known in the art by standard manipulation of commercially available or known materials.

It will also be appreciated that in some of the reactions mentioned herein it may be
15 necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Thus, if reactants include groups such as carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for
20 example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
25 Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed,
30 for example, by treatment with an acid, for example an organic acid such as trifluoroacetic

acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

5 Some of the intermediates described herein may be novel, for example intermediates of the formula (II), and as such they are provided as a further feature of the invention.

When a pharmaceutically-acceptable salt of a compound of formula (I) is required, it may be obtained, for example, by reaction of said compound with the appropriate acid (which affords a physiologically acceptable anion), or with the appropriate base (which affords a
10 physiologically acceptable cation), or by any other conventional salt formation procedure.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I) as defined hereinbefore or a pharmaceutically acceptable salt or prodrug thereof, in association with a pharmaceutically acceptable excipient or carrier.

15 The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for
20 example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended
25 for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding
30 agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their

- 13 -

disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting

agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil,
5 or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and
10 condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

15 The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a
20 solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

25 Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided
30 powder containing particles of average diameter of, for example, 30 μ or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then

- 15 -

conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional
5 pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in
10 Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration
15 to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in
20 Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known
25 principles of medicine. As mentioned above, compounds of the Formula I are useful in treating diseases or medical conditions which are due alone or in part to the effects of MCP-1 and/or RANTES, for example, rheumatoid arthritis.

In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per
30 kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will

generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

According to a further aspect of the present invention there is provided a compound of
5 the formula (I) or a pharmaceutically acceptable salt or prodrug thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy. Conveniently, the invention provides a method of treating inflammatory disease by administering a compound of formula (I) or a pharmaceutically acceptable salt or prodrug or a pharmaceutical composition thereof, as described above.

10 A further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salt or prodrug thereof, for use as a medicament.

Conveniently this is a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, for use as a medicament for antagonising an MCP-1 mediated effect (and/or a RANTES mediated effect) in a warm-blooded animal such as a human being.

15 Thus according to a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for use in antagonising an MCP-1 mediated effect (and/or a RANTES mediated effect) in a warm-blooded animal such as a human being.

According to a further feature of the invention there is provided a method of
20 antagonising an MCP-1 mediated effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof, as defined hereinbefore.

Biological Testing.

25 The following biological test methods, data and Examples serve to illustrate the present invention.

Abbreviations:

ATCC	American Type Culture Collection, Rockville, USA.
BCA	Bicinchronic acid, (used, with copper sulphate, to assay protein)
BSA	Bovine Serum Albumin
DMEM	Dulbecco's modified Eagle's medium

- 17 -

EGTA	Ethylenebis(oxyethylenenitrilo)tetraacetic acid
FCS	Foetal calf serum
HEPES	(N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulphonic acid])
HBSS	Hank's Balanced Salt Solution
hMCP-1	Human Monocyte Chemoattractant Protein-1
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% foetal calf serum, adjusted to pH 7.2 with 1 M NaOH.

- 5 Non-Essential Amino Acids (100X concentrate) is: L-Alanine, 890 mg/l; L-Asparagine, 1320 mg/l; L-Aspartic acid, 1330 mg/l; L-Glutamic acid, 1470 mg/l; Glycine, 750 mg/l; L-Proline, 1150 mg/l and; L-Serine, 1050 mg/l.

Hypoxanthine and Thymidine Supplement (50x concentrate) is: hypoxanthine, 680 mg/l and; thymidine, 194 mg/l.

- 10 Penicillin-Streptomycin is: Penicillin G (sodium salt); 5000 units/ml; Streptomycin sulphate, 5000 µg/ml.

Human monocytic cell line THP-1 cells are available from ATCC, accession number ATCC TIB-202.

- Hank's Balanced Salt Solution (HBSS) was obtained from Gibco; see *Proc. Soc. Exp. Biol. Med.*, 1949, 71, 196.

Synthetic cell culture medium, RPMI 1640 was obtained from Gibco; it contains inorganic salts [Ca(NO₃)₂·4H₂O 100 mg/l; KCl 400 mg/l; MgSO₄·7H₂O 100 mg/l; NaCl 6000 mg/l; NaHCO₃ 2000 mg/l & Na₂HPO₄ (anhyd) 800 mg/l], D-Glucose 2000 mg/l, reduced glutathione 1 mg/l, amino acids and vitamins.

- 20 FURA-2/AM is 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)-ethane-*N,N,N',N'*-tetraacetic acid pentaacetoxymethyl ester and was obtained from Molecular Probes, Eugene, Oregon, USA.

Blood Sedimentation Buffer contains 8.5g/l NaCl and 10g/l hydroxyethyl cellulose.

Lysis Buffer is 0.15M NH₄Cl, 10mM KHCO₃, 1mM EDTA

Whole Cell Binding Buffer is 50 mM HEPES, 1 mM CaCl₂, 5 mM MgCl₂, 0.5% BSA, 0.01% NaN₃, adjusted to pH 7.2 with 1M NaOH.

Wash buffer is 50mM HEPES, 1mM CaCl₂, 5mM MgCl₂, 0.5% heat inactivated FCS, 0.5MNaCl adjusted to pH7.2 with 1M NaOH.

- 5 General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

i) Cloning and expression of hMCP-1 receptor

- 10 The MCP-1 receptor B (CCR2B) cDNA was cloned by PCR from THP-1 cell RNA using suitable oligonucleotide primers based on the published MCP-1 receptor sequences (Charo *et al.*, 1994, *Proc. Natl. Acad. Sci. USA*, 91, 2752). The resulting PCR products were cloned into vector PCR-II™ (InVitrogen, San Diego, CA.). Error free CCR2B cDNA was subcloned as a Hind III-Not I fragment into the eukaryotic expression vector pCDNA3
- 15 (InVitrogen) to generate pCDNA3/CC-CKR2A and pCDNA3/CCR2B respectively.

- Linearised pCDNA3/CCR2B DNA was transfected into CHO-K1 cells by calcium phosphate precipitation (Wigler *et al.*, 1979, *Cell*, 16, 777). Transfected cells were selected by the addition of Geneticin Sulphate (G418, Gibco BRL) at 1mg/ml, 24 hours after the cells had been transfected. Preparation of RNA and Northern blotting were carried out as described
- 20 previously (Needham *et al.*, 1995, *Prot. Express. Purific.*, 6, 134). CHO-K1 clone 7 (CHO-CCR2B) was identified as the highest MCP-1 receptor B expressor.

ii) Preparation of membrane fragments

- CHO-CCR2B cells were grown in DMEM supplemented with 10% foetal calf serum, 2 mM glutamine, 1x Non-Essential Amino Acids, 1x Hypoxanthine and Thymidine
- 25 Supplement and Penicillin-Streptomycin (at 50 µg streptomycin/ml, Gibco BRL). Membrane fragments were prepared using cell lysis/differential centrifugation methods as described previously (Siciliano *et al.*, 1990, *J. Biol. Chem.*, 265, 19658). Protein concentration was estimated by BCA protein assay (Pierce, Rockford, Illinois) according to the manufacturer's instructions.

30 iii) Assay

- ¹²⁵I MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, 133, 529; Amersham International plc]. Equilibrium binding assays were carried

out using the method of Ernst *et al.*, 1994, *J. Immunol.*, **152**, 3541. Briefly, varying amounts of ^{125}I -labeled MCP-1 were added to 7 μg of purified CHO-CCR2B cell membranes in 100 μl of Binding Buffer. After 1 hour incubation at room temperature the binding reaction mixtures were filtered and washed 5 times through a plate washer (Brandel MLR-96T Cell Harvester) using ice cold Binding Buffer. Filter mats (Brandel GF/B) were pre-soaked for 60 minutes in 0.3% polyethylenimine prior to use. Following filtration individual filters were separated into 3.5ml tubes (Sarstedt No. 55.484) and bound ^{125}I -labeled MCP-1 was determined (LKB 1277 Gammamaster). Cold competition studies were performed as above using 100 pM ^{125}I -labeled MCP-1 in the presence of varying concentrations of unlabelled MCP-1. Non-specific binding was determined by the inclusion of a 200-fold molar excess of unlabelled MCP-1 in the reaction.

Ligand binding studies with membrane fragments prepared from CHO-CCR2B cells showed that the CCR2B receptor was present at a concentration of 0.2 pmoles/mg of membrane protein and bound MCP-1 selectively and with high affinity ($\text{IC}_{50} = 110 \text{ pM}$, $K_d = 120 \text{ pM}$). Binding to these membranes was completely reversible and reached equilibrium after 45 minutes at room temperature, and there was a linear relationship between MCP-1 binding and CHO-CCR2B cell membrane concentration when using MCP-1 at concentrations between 100 pM and 500 pM.

Test compounds dissolved in DMSO (5 μl) were tested in competition with 100 pM labelled MCP-1 over a concentration range (0.01-50 μM) in duplicate using eight point dose-response curves and IC_{50} concentrations were calculated.

Compounds tested of the present invention had IC_{50} values of 50 μM or less in the hMCP-1 receptor binding assay described herein.

b) MCP-1 mediated calcium flux in THP-1 cells

The human monocytic cell line THP-1 was grown in a synthetic cell culture medium RPMI 1640 supplemented with 10 % foetal calf serum, 6mM glutamine and Penicillin-Streptomycin (at 50 μg streptomycin/ml, Gibco BRL). THP-1 cells were washed in HBSS (lacking Ca^{2+} and Mg^{2+}) + 1 mg/ml BSA and resuspended in the same buffer at a density of 3×10^6 cells/ml. The cells were then loaded with 1mM FURA-2/AM for 30 min at 37°C, washed twice in HBSS, and resuspended at 1×10^6 cells/ml. THP-1 cell suspension (0.9 ml) was added to a 5 ml disposable cuvette containing a magnetic stirrer bar and 2.1 ml of prewarmed (37°C) HBSS containing 1 mg/ml BSA, 1 mM MgCl_2 and 2 mM CaCl_2 . The

- 20 -

cuvette was placed in a fluorescence spectrophotometer (Perkin Elmer, Norwalk, CT) and preincubated for 4 min at 37°C with stirring. Fluorescence was recorded over 70 sec and cells were stimulated by addition of hMCP-1 to the cuvette after 10 sec. $[Ca^{2+}]_i$ was measured by excitation at 340 nm and 380 nm alternately and subsequent measurement of the intensity of the fluorescence emission at 510 nm. The ratio of the intensities of the emitted fluorescent light following excitation at 340 nm and 380 nm, (R), was calculated and displayed to give and estimate of cytoplasmic $[Ca^{2+}]$ according to the equation:-

$$[Ca^{2+}]_i = K_d \frac{(R - R_{min})}{(R_{max} - R)} \left(\frac{Sf2/Sb2}{Sf2/Sb2} \right)$$

10 where the K_d for FURA-2 Ca^{2+} complex at 37°C was taken to be 224nm. R_{max} is the maximal fluorescence ratio determined after addition of 10 mM Ionomycin, R_{min} is the minimal ratio determined by the subsequent addition of a Ca^{2+} free solution containing 5 mM EGTA, and Sf2/Sb2 is the ratio of fluorescence values at 380 nm excitation determined at R_{min} and R_{max} , respectively.

15 Stimulation of THP-1 cells with hMCP-1 induced a rapid, transient rise in $[Ca^{2+}]_i$ in a specific and dose dependent manner. Dose response curves indicated an approximate EC_{50} of 2 nm. Test compounds dissolved in DMSO (10µl) were assayed for inhibition of calcium release by adding them to the cell suspension 10 sec prior to ligand addition and measuring the reduction in the transient rise in $[Ca^{2+}]_i$. Test compounds were also checked for lack of
20 agonist activity by addition in place of hMCP-1.

c) hMCP-1 and RANTES mediated chemotaxis.

In vitro chemotaxis assays were performed using the human monocytic cell line THP-1. Cell migration through polycarbonate membranes was measured by enumerating those passing through either directly by Coulter counting or indirectly by use of a colourimetric
25 viability assay measuring the cleavage of a tetrazolium salt by the mitochondrial respiratory chain (Scudiero D.A. *et al.* 1988, *Cancer Res.*, 48, 4827-4833).

Chemoattractants were introduced into a 96-well microtitre plate which forms the lower well of a chemotaxis chamber fitted with a PVP-free 5 µm poresize polycarbonate adhesive framed filter membrane (NeuroProbe MB series, Cabin John, MD 20818, USA)
30 according to the manufacturer's instructions. The chemoattractant was diluted as appropriate in synthetic cell culture medium, RPMI 1640 (Gibco) or supplemented with 2 mM glutamine and 0.5% BSA, or alternatively with HBSS with Ca^{2+} and Mg^{2+} without Phenol Red (Gibco)

- 21 -

plus 0.1% BSA. Each dilution was degassed under vacuum for 30 min and was placed (400 μ l) in the lower wells of the chamber and THP-1 cells (5×10^5 in 100 μ l RPMI 1640 + 0.5% BSA) were incubated in each well of the upper chamber. For the inhibition of chemotaxis the chemoattractant was kept at a constant submaximal concentration determined previously (1nM MCP-1) and added to the lower well together with the test compounds dissolved in DMSO (final DMSO concentration < 0.05% v/v) at varying concentrations. The chamber was incubated for 2 h at 37°C under 5 % CO₂. The medium was removed from the upper wells which were then washed out with 200 μ l physiological saline before opening the chamber, wiping dry the membrane surface and centrifuging the 96-well plate at 600 g for 5 min to harvest the cells. Supernatant (150 μ l) was aspirated and 10 μ l of cell proliferation reagent, WST-1, {4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-phenyl disulfonate} plus an electron coupling reagent (Boehringer Mannheim, Cat.no. 1644 807) was added back to the wells. The plate was incubated at 37°C for 3 h and the absorbance of the soluble formazan product was read on a microtitre plate reader at 450 nm. The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average absorbance values, standard error of the mean, and significance tests were calculated. hMCP-1 induced concentration dependent cell migration with a characteristic biphasic response, maximal 0.5-1.0 nm.

In an alternative form of the above assay, fluorescently tagged cells can be used in order to assist in end point detection. In this case, the THP-1 cells used are fluorescently tagged by incubation in the presence of 5mM Calcein AM (Glycine, N,N'-[[3',6'-bis(acetyloxy)-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthene]-2',7'-diyl]bis(methylene)]bis[N-[2-[(acetyloxy)methoxy]-2-oxoethyl]]-bis[(acetyloxy)methyl] ester; Molecular Probes) for 45 minutes in the dark. Cells are harvested by centrifugation and resuspended in HBSS (without Phenol Red) with Ca²⁺, Mg²⁺ and 0.1% BSA. 50 μ l (2×10^5 cells) of the cell suspension are placed on the filter above each well and, as above, the unit is incubated at 37°C for 2 hours under 5% CO₂. At the end of the incubation, cells are washed off the upper face of the filter with phosphate buffered saline, the filter removed from the plate and the number of cells attracted to either the underside of the filter or the lower well estimated by reading fluorescence at 485nm excitation, 538nm emission wavelengths (fmax, Molecular Devices). The data was input into a spreadsheet, corrected for any random migration in the absence of chemoattractant and the average fluorescence values, standard error of the mean, percentage

- 22 -

inhibition and IC_{50} of compounds under test and significance tests can be calculated. In addition to MCP-1 induced chemotaxis, this alternative form of the assay was also used to measure inhibition of RANTES (2nM) induced chemotaxis.

d) Binding to human peripheral blood mononuclear cells(PBMCs)

5 **i) Preparation of human PBMCs**

Fresh human blood (200ml) was obtained from volunteer donors, collected into sodium citrate anticoagulant to give a final concentration of 0.38%. The blood was mixed with Sedimentation Buffer and incubated at 37°C for 20 minutes. The supernatant was collected and centrifuged at 1700rpm for 5 minutes (Sorvall RT6000D). The pellet obtained
10 was resuspended in 20 ml RPMI/BSA (1mg/ml) and 4 x 5mls of cells were carefully layered over 4 x 5mls of Lymphoprep™ (Nycomed) in 15ml centrifuge tubes. Tubes were spun at 1700rpm for 30 minutes (Sorvall RT6000D) and the resultant layer of cells was removed and transferred to 50ml Falcon tubes. The cells were washed twice in Lysis Buffer to remove any remaining red blood cells followed by 2 washes in RPMI/BSA. Cells were resuspended in
15 5mls of Binding Buffer. Cell number was measured on a Coulter counter and additional binding buffer was added to give a final concentration of 1.25×10^7 PBMCs /ml.

ii) Assay

[^{125} I]MCP-1 was prepared using Bolton and Hunter conjugation (Bolton *et al.*, 1973, *Biochem. J.*, 133, 529; Amersham International plc]. Equilibrium binding assays were carried
20 out using the method of Ernst *et al.*, 1994, *J. Immunol.*, 152, 3541. Briefly, 50µl of ^{125} I-labeled MCP-1 (final concentration 100pM) was added to 40µl (5×10^5 cells) of cell suspension in a 96 well plate. Compounds, diluted in Whole Cell Binding Buffer from a stock solution of 10mM in DMSO were added in a final volume of 5µl to maintain a constant DMSO concentration in the assay of 5%. Total binding was determined in the absence of
25 compound. Non-specific binding was defined by the addition of 5µl cold MCP-1 to give a final assay concentration of 100nM. Assay wells were made up to a final volume of 100µl with Whole Cell Binding Buffer and the plates sealed. Following incubation at 37°C for 60 minutes the binding reaction mixtures were filtered and washed for 10 seconds using ice cold Wash Buffer using a plate washer (Brandel MLR-96T Cell Harvester). Filter mats (Brandel
30 GF/B) were pre-soaked for 60 minutes in 0.3% polyethylenimine plus 0.2% BSA prior to use. Following filtration individual filters were separated into 3.5ml tubes (Sarstedt No. 55.484) and bound ^{125} I-labeled MCP-1 was determined (LKB 1277 Gammamaster).

Test compound potency was determined by assay in duplicate using six point dose-response curves and IC₅₀ concentrations were determined.

No physiologically unacceptable toxicity was observed at the effective dose for compounds tested of the present invention.

- 5 The invention is further illustrated, but not limited by the following Examples in which the following general procedures were used unless stated otherwise.
- i) N,N-Dimethylformamide (DMF) was dried over 4Å molecular sieves. Anhydrous tetrahydrofuran (THF) was obtained from Aldrich SURESEAL™ bottles. Other commercially available reagents and solvents were used without further purification unless otherwise stated.
- 10 Organic solvent extracts were dried over anhydrous MgSO₄.
- ii) ¹H, ¹³C and ¹⁹F NMR were recorded on Bruker WM200, WM250, WM300 or WM400 instruments using DMSO-d₆ with Me₄Si or CCl₃F as internal standard as appropriate, unless otherwise stated. Chemical shifts are quoted in δ (ppm) and peak multiplicities are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q,
- 15 quartet; m, multiplet; br, broad.
- iii) Mass spectra were recorded on VG 12-12 quadrupole, VG 70-250 SE, VG ZAB 2-SE or a VG modified AEI/Kratos MS9 spectrometers.
- iv) For TLC analysis, Merck precoated TLC plates (silica gel 60 F254, d = 0.25 mm) were used.
- 20 v) Flash chromatography was performed on silica (Merck Kieselgel: Art.9385).

Example 1

N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid

- Sodium hydroxide (1M, 100 ml) was added to a stirred solution of ethyl N-(3-
- 25 trifluoromethyl-4-chlorobenzyl)-5-acetoxyindole-2-carboxylate (11.82 g) in water (50 ml) and methanol (150 ml). The reaction was stirred at 55°C for 6 hours. The methanol was removed under *vacuo* and the remaining solution was acidified by the addition of aqueous hydrochloric acid (2M, 50 ml) precipitating the product as a white solid. The product was filtered, washed with water and dried in *vacuo* to yield a cream solid (9.53 g,) which was purified by column
- 30 chromatography using ethylacetate as the eluant. Crystallisation from methanol/water yielded the title compound as a cream solid (7.08 g, 71%) NMR: (CD₃SOCD₃) δ 5.84 (s, 2H), 6.83

(dd, 1H), 6.95 (d, 1H), 7.11-7.19 (m, 2H), 7.36 (d, 1H), 7.55-7.64 (m, 2H), 9.03 (s, 1H); m/z 368 (M-H⁺).

The procedure described in the above example was repeated using the appropriate indole ester
5 as the starting materials. Thus were obtained the compounds described below.

Example 2

N-(3-fluoro-4-trifluoromethylbenzyl)-5-hydroxyindole-2-carboxylic acid

50% yield. NMR (CD₃SOCD₃) δ 5.87 (s, 2H), 6.85 (m, 2H), 6.99 (dd, 1H), 7.11 (d, 1H), 7.17 (s, 1H), 7.33 (d, 1H), 7.67 (t, 1H); m/z 352 (M-H⁺).

10 **Example 3**

N-(3-chloro-4-trifluoromethylbenzyl)-5-hydroxyindole-2-carboxylic acid

(55% yield). NMR(CD₃SOCD₃) δ: 5.9 (s, 2H), 6.9 (m, 1H), 7.1 (m, 2H), 7.25 (s, 1H), 7.4 (m, 2H), 7.8 (d, 1H), 9.1 (s, 1H); m/z 368/370 (M-H⁺).

Example 4

15 N-(3-bromo-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid

71% yield. NMR (CD₃SOCD₃) δ 5.76 (s, 2H), 6.80 (d, 1H), 6.95 (m, 2H), 7.12 (s, 1H), 7.36 (d, 1H), 7.40 (s, 1H), 7.47 (d, 1H), 9.00 (s, 1H); m/z 380 (MH⁺).

Example 5

N-(3-fluoro-4-bromobenzyl)-5-hydroxyindole-2-carboxylic acid

20 53% yield. NMR (CD₃SOCD₃) δ 5.77 (s, 1H), 6.70 (d, 1H), 6.80 (dd, 1H), 6.96 (s, 1H), 7.00 (d, 1H), 7.17 (s, 1H), 7.32 (d, 1H), 7.57 (t, 1H), 9.00 (s, 1H), 12.82 (s, 1H); m/z 362 (M-H⁺).

Example 6

N-(3-bromo-4-fluorobenzyl)-5-hydroxyindole-2-carboxylic acid

25 55% yield. NMR (CD₃SOCD₃) δ 5.77 (s, 2H), 6.80 (dd, 1H), 6.97 (d, 1H), 6.99 (m, 1H), 7.13 (s, 1H), 7.23 (t, 1H), 7.38 (m, 2H), 9.00 (s, 1H); m/z 362 (M-H⁺).

Example 7

N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylic acid

(58% yield). NMR(CD₃SOCD₃) δ: 5.85 (s, 2H), 7.0 (t, 1H), 7.1 (m, 2H), 7.2-7.3 (m, 3H), 7.4 (t, 1H), 7.95 (dd, 1H), 9.3 (s, 1H) 13.1 (s, 1H); m/z 370 (M-H⁺).

30 **Example 8**

N-(3-trifluoromethyl-4-chlorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylic acid

97% yield. NMR (CD₃SOCD₃) δ 5.80 (s, 2H), 7.00 (t, 1H), 7.16 (dd, 1H), 7.20 (m, 2H), 7.60 (m, 2H), 9.30 (s, 1H); m/z 386 (M-H⁺).

Example 9

N-(3-trifluoromethyl-4-fluorobenzyl)-4,6-difluoro-5-hydroxyindole-2-carboxylic acid

- 5 83% yield. NMR (CD₃SOCD₃) δ 5.80(s, 2H), 7.20(s, 1H), 7.23(m, 1H), 7.30-7.50(m, 2H), 7.58(m, 1H), 9.60(s, 1H); M/z(-) 388.2 (M-H⁺)

Example 10

N-(3, 4-chlorobenzyl)-4,6-dichloro-5-hydroxyindole-2-carboxylic acid

- 82% yield. NMR (CD₃SOCD₃) δ 5.92 (s, 2H), 6.87 (s, 1H), 6.99 (dd, 1H), 7.37 (d, 1H), 7.5 (d, 1H), 7.55 (s, 1H); m/z 406, 404, 402 (M-H⁺)

Example 11

N-(3-trifluoromethyl-4-fluorobenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid

(92% yield). NMR(CD₃SOCD₃) δ : 5.8 (s, 2H), 6.9 (m, 2H), 7.25 (dd, 1H), 7.35-7.55 (m, 2 H), 7.6 (dd, 1H), 9.4 (s, 1H); m/z 430/432 (M-H⁺).

15 **Example 12**

N-(3-trifluoromethyl-4-chlorobenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid

(309mg, 87%). NMR(CD₃SOCD₃) δ :: 5.85 (s, 2H), 6.8-7.0 (m, 3H), 7.4 (d, 1H), 7.75 (d, 1H), 9.4 (s, 1H); m/z 446/448 (M-H⁺).

Example 13

- 20 N-(3-chloro-4-trifluoromethylbenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid

(82% yield) NMR(CD₃SOCD₃) δ :: 5.8 (s, 2H), 6.9 (m, 2H), 7.1 (dd, 1H), 7.45 (d, 1H), 7.6 (m, 2H), 9.4 (s, 1H) ; m/z 447 (M-H⁺).

Example 14

N-(3-fluoro-4-trifluoromethylbenzyl)-3-chloro-5-hydroxyindole-2-carboxylic acid

- 25 NMR (CD₃SOCD₃) δ 5.8 (s, 2H), 6.9(m, 2H), 7.25(m, 1H), 7.4(m, 2H), 7.6(d, 1H), 9.4(s, 1H); m/z 386.0(M-H⁺).

Example 15

N-(3-fluoro- 4-trifluoromethylbenzyl)-3-iodo-5-hydroxyindole-2-carboxylic acid

- 25 NMR (CD₃SOCD₃) δ 5.8 (s, 2H), 6.8(s, 1H), 6.9(d, 1H), 7.2(m, 1H), 7.4(m, 2H), 7.6(d, 1H), 9.3(s, 1H); m/z 478(M-H⁺).

30 **Example 16**

N-(3-trifluoromethyl-4-chlorobenzyl)-3-methoxy-5-hydroxyindole-2-carboxylic acid

(108% yield as hydrate) NMR: 3.9 (s, 3H) 5.7 (s, 2H), 6.8 (dd, 1H), 6.9 (d, 1H), 7.2 (d, 1H) 7.4 (d, 1H), 7.6 (m, 2H), 9.1 (s, 1H); m/z 398 ($M-H^+$).

Example 175 *N*-(3-trifluoromethyl-4-fluorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid

(68% yield). NMR (CD_3SOCD_3) δ 5.8 (s, 2H), 7.1-7.2 (m, 3H), 7.4-7.55 (m, 2H), 7.7 (s, 1H), 9.8 (s, 1H); m/z 386 ($M-H^+$).

Example 18*N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid

10 71% yield. NMR (CD_3SOCD_3) δ 5.74 (s, 2H), 7.04-7.21 (m, 3H), 7.53-7.63 (m, 2H), 7.7 (s, 1H), 9.72 (bs, 1H); m/z 402.1/404.5 ($M-H^+$)

Example 19*N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-7-fluoroindole-2-carboxylic acid

15 55% yield. NMR (CD_3SOCD_3) δ 5.90 (s, 2H), 6.60 (m, 1H), 6.80 (m, 1H), 7.15 (m, 2H), 7.52 (m, 1H), 7.60 (d, 1H); $M/z(-)$ 385.85 ($M-H^+$)

Example 20*N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-bromoindole-2-carboxylic acid

20 90% yield. NMR (CD_3SOCD_3) δ 5.82 (s, 2H), 7.10 (m, 1H), 7.18 (d, 2H), 7.60 (m, 2H), 7.82 (s, 1H), 9.80 (s, 1H), 13.0 (s, 1H); m/z 446.18 ($M-H^+$)

Example 21*N*-(3,4-dichlorobenzyl)-5-hydroxy-6-bromoindole-2-carboxylic acid

92% yield. NMR (CD_3SOCD_3) δ 5.80 (s, 2H), 6.85 (m, 1H), 7.15 (s, 2H), 7.25 (m, 1H), 7.50 (d, 1H), 7.80 (s, 1H), 9.80 (s, 1H); m/z 412.1 ($M-H^+$)

Example 22*N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylic acid

97% yield. NMR (CD_3SOCD_3) δ 5.8 (s, 2H), 7.1-7.2 (m, 3H), 7.49 (d, 1H), 7.55-7.63 (m, 2H), 9.49 (s, 1H), 12.86 (bs, 1H); m/z 386, 388 ($M-H^+$)

30 **Example 23***N*-(3,4-dichlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylic acid

97% yield. NMR (CD_3SOCD_3) δ 5.75 (s, 2H), 6.9 (dd, 1H), 7.1-7.2 (m, 2H), 7.3 (d, 1H), 7.45 (d, 1H), 7.5 (d, 1H), 9.5 (bs, 1H); m/z 353 ($M-H^+$)

Example 24*N*-(3,4-dichlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid

41% yield. NMR (CD₃SOCD₃) δ 5.8 (s, 2H), 6.9 (dd, 1H), 7.2 (s, 2H), 7.3 (d, 1H), 7.5 (d, 1H), 7.65 (s, 1H), 9.75 (s, 1H); m/z 398, 396 (M-H⁺)

5 Example 25*N*-(3-trifluoromethyl-4-chlorobenzyl)-4-chloro-5-hydroxyindole-2-carboxylic acid

93% yield. NMR (CD₃SOCD₃) δ 5.86 (s, 2H), 7.01 (d, 1H), 7.09-7.13 (m, 2H), 7.4 (d, 1H), 7.58-7.68 (m, 2H), 9.66 (bs, 1H); m/z 402, 404 (M-H⁺).

Example 26**10** *N*-(3-trifluoromethyl-4-chlorobenzyl)-4,6-dichloro-5-hydroxyindole-2-carboxylic acid

76% yield. NMR (CD₃SOCD₃) δ 5.86 (s, 2H), 7.09 (dd, 1H), 7.15 (s, 1H), 7.59 (d, 1H), 7.64 (d, 1H), 7.81 (s, 1H), 9.64 (bs, 1H); m/z 392, 394 (M-H⁺).

Example 27*N*-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxyindole-2-carboxylic acid (Prodrug of**15** compound No. 1 of Example 1)

To a solution of *N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid (1.01g) in warm ethyl acetate (80ml)-was added 4-dimethylaminopyridine (30mg) and acetic anhydride (0.64ml) and the resulting mixture was stirred for 18 hours. The organics were washed with 1N HCl and dried. The organics were concentrated and purified by column
20 chromatography, eluting with ethyl acetate to give the desired product(808 mg, 72%). ¹H NMR (DMSO-d₆) δ 2.25 (s, 3H), 5.9 (s, 2H), 7.05 (m, 1H), 7.15 (m, 1H), 7.32 (s, 1H), 7.43 (d, 1H), 7.60 (m, 2H), 7.65 (d, 1H); m/z 410 (M-H⁺).

Preparation of Starting Materials

25 The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions (Methods A-E) are illustrations but not limitations of the preparation of the starting materials used in the above reactions.

30 Method AEthyl 5-acetoxy-*N*-(3-trifluoromethyl-4-chlorobenzyl)indole-2-carboxylatei) Ethyl 5-hydroxyindole-2-carboxylate

Boron tribromide (64.58 g) was added dropwise to a stirred solution of ethyl 5-methoxyindole-2-carboxylate (20 g) in dichloromethane (1000 ml) at -78°C under an atmosphere of argon. The reaction was allowed to warm to room temperature and stirred for a further 2 hours. The reaction was poured into ice / saturated aqueous sodium hydrogen carbonate solution with stirring and extracted with ethyl acetate. Combined organic extracts were washed with saturated aqueous sodium hydrogen carbonate solution, water, aqueous saturated sodium chloride solution and dried. The solution was concentrated *in vacuo* and the residue was purified by column chromatography using 0 - 60% diethyl ether: *iso*-hexane as eluent to yield product as a white solid (9.02 g, 48%). NMR(CD₃SOCD₃): δ 1.31 (t, 3H), 4.29 (q, 2H), 6.79 (dd, 1H), 6.90 (dd, 1H), 7.22 (d, 1H), 8.84 (s, 1H), 11.52 (brs, 1H); m/z 206 (MH⁺).

ii) Ethyl 5-acetoxyindole-2-carboxylate

A stirred solution of ethyl 5-hydroxyindole-2-carboxylate (7.79 g) and 4-dimethylaminopyridine (20 mg) in acetic anhydride (80 ml) was heated at 80°C for 4 hours. The reaction was concentrated *in vacuo* and the residue was dissolved in ethyl acetate. Combined organic extracts were washed with hydrochloric acid (2 M), saturated aqueous sodium hydrogen carbonate solution, water, aqueous saturated sodium chloride solution and dried. The solution was concentrated *in vacuo* to yield the product as a yellow solid (9.39 g, 100 %). NMR(CD₃SOCD₃): δ 1.20 (t, 3H), 2.10 (s, 3H), 4.19 (q, 2H), 6.86 (dd, 1H), 6.97 (d, 1H), 7.20 (s, 1H), 7.29 (d, 1H); m/z 248 (MH⁺).

iii) Ethyl 5-acetoxy-N-(3-trifluoromethyl-4-chlorobenzyl)indole-2-carboxylate

Sodium hydride (1.78 g) was added to a stirred solution of ethyl 5-acetoxyindole-2-carboxylate (10 g) and 3-trifluoromethyl-4-chlorobenzylbromide (11.64 g) in DMF (200 ml) under an atmosphere of argon. The reaction was stirred at ambient temperature for 16 hours, then concentrated *in vacuo* and the residue partitioned between ethyl acetate and water. Combined organic extracts were dried, concentrated under *vacuo* and purified by column chromatography using *i*-hexane-15%ethylacetate/*iso*hexane as the eluant to yield a cream solid. Crystallisation from ethylacetate/*iso*hexane yielded the product as a cream solid (13.26 g, 74%). NMR (CD₃SOCD₃): δ 1.37 (t, 3H), 2.31 (s, 3H), 4.32 (q, 2H), 5.82 (s, 2H), 7.0-7.09 (m, 2H), 7.22 - 7.29 (m, 1H), 7.31-7.4 (m, 2H) 7.43 (d, 1H), 7.51 (s, 1H).

The procedures described in Method A i) - iii) were repeated using the appropriate benzyl halide. Thus were obtained the compounds described below.

5 Ethyl N-(3-fluoro-4-trifluoromethylbenzyl)-5-acetoxyindole-2-carboxylate

860mg, 96% NMR (CDCl₃) δ 1.39 (t, 3H), 2.36 (s, 3H), 4.37 (q, 2H), 5.83 (s, 2H), 6.83 (d, 1H), 6.90 (d, 1H), 7.08 (dd, 1H), 7.23 (s, 1H), 7.40 (s, 1H), 7.42 (d, 1H), 7.50 (t, 1H); m/z 424 (MH⁺).

10 Ethyl N-(3-chloro-4-trifluoromethylbenzyl)-5-acetoxyindole-2-carboxylate

55% yield. NMR (CDCl₃) δ 1.4 (t, 3H) 2.3 (s, 3H) 4.3 (q, 2H) 5.8 (s, 2H), 6.95 (d, 1H), 7.1 (dd, 2H), 7.2 (m, 2H), 7.4 (s, 1H), 7.45 (d, 1H) 7.55 (d, 1H); m/z 440/422 (M+H⁺).

Ethyl N-(3-bromo-4-chlorobenzyl)-5-acetoxyindole-2-carboxylate

15 15% yield. NMR (CDCl₃) δ 1.37 (t, 3H), 2.30 (s, 3H), 4.31 (q, 2H), 5.74 (s, 2H), 6.83 (d, 1H), 7.03 (dd, 1H), 7.24 (m, 2H), 7.37 (m, 2H), 7.40 (d, 1H). m/z 449 (MH⁺).

Ethyl N-(3-fluoro-4-bromobenzyl)-5-acetoxyindole-2-carboxylate

77% yield. NMR (CDCl₃) δ 1.37 (t, 3H), 2.30 (s, 3H), 4.37 (q, 2H), 5.77 (s, 2H), 6.72 (d, 1H),
20 6.74 (d, 1H), 7.03 (dd, 1H), 7.23 (m, 1H), 7.37 (s, 1H), 7.40 (t, 1H).

Ethyl N-(3-bromo-4-fluorobenzyl)-5-acetoxyindole-2-carboxylate

41% yield. NMR (CDCl₃) δ 1.40 (t, 3H), 2.34 (s, 3H), 4.37 (q, 2H), 5.72 (s, 2H), 6.95 (dd, 1H), 7.05 (dd, 1H), 7.23 (m, 2H), 7.37 (s, 1H), 7.40 (d, 1H), 7.62 (d, 1H); m/z 433 (MH⁺).

25

Method B

Methyl-N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylate

(i) 2-Fluoro-3-benzyloxybenzaldehyde

30 2-Fluoro-3-hydroxybenzaldehyde (16.49g) was dissolved in dimethylformamide (200ml) and stirred under an argon atmosphere. Sodium hydride was added (60% in mineral oil, 5.18g) and the mixture was stirred for 30 minutes. Benzyl bromide was added (16.8ml)

- 30 -

and the mixture was stirred overnight. Reaction mixture was concentrated *in vacuo* and the resulting residue was partitioned between diethyl ether (200ml) and water (200ml). Combined organic extracts were washed with water (400ml), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash column chromatography, using a gradient of 0-10% ethyl acetate/iso-hexane as eluent to give the desired product as a yellow solid (18.41g, 68%): ¹H NMR (CD₃SOCD₃) δ 5.20 (s, 2H), 7.2-7.6 (m, 8H), 10.21(s, 1H)

10 (ii) Methyl-2-azido-3-(2-fluoro-3-benzyloxyphenyl)propenoate

A mixture of methylazidoacetate (36.64g) and 2-Fluoro-3-benzyloxy benzaldehyde (18.32g) in methanol (250ml) was added dropwise, with stirring, over 1 hour to a mixture of sodium methoxide (17.20g) in methanol (100ml) at -25°C under a stream of argon. Mixture was left to stir for 20 minutes, allowed to warm to 5°C and stirred overnight.

15 The resulting precipitate was filtered, then washed sequentially with cold methanol, dilute solution of acetic acid in water and water. The resulting solid was dried under vacuum to give the product as a pale brown solid (16.70g) which was used without purification.

20 (iii) Methyl-4-fluoro-5-benzyloxyindole-2-carboxylate

A solution of methyl-2-azido-3-(2-fluoro-3-benzyloxyphenyl)propenoate (16.7g) in xylene (600ml) was added dropwise with stirring to refluxing xylene (2.4L) over 1 hour and then stirred for a further 20 minutes. The reaction mixture was concentrated *in vacuo* and
25 purified by flash column chromatography, using a gradient of 0-100% ethyl acetate/iso-hexane as eluent to give the product as a yellow solid (12.93g, 54%). ¹H NMR (CD₃SOCD₃) δ 3.85(s, 3H), 5.15 (s, 2H), 7.05-7.45 (m, 8H), 12.06 (s, 1H); m/z 300.4 (MH⁺)

In a similar manner, steps (ii) and (iii) were repeated, but using 2-chloro-3-methoxybenzaldehyde and ethyl azidoacetate was prepared:-

30 Ethyl-4-chloro-5-methoxyindole-2-carboxylate

¹H NMR (CD₃SOCD₃) δ 1.31 (t, 3H), 3.84 (s, 3H), 4.32 (q, 2H), 7.0 (d, 1H), 7.22 (d, 1H), 7.39 (d, 1H), 12.2 (bs, 1H).

(iv) Methyl-N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-benzyloxyindole-2-carboxylate

Sodium hydride (60% in mineral oil, 75mg) was added to a solution of methyl-4-fluoro-5-benzyloxyindole-2-carboxylate (257mg) in dimethylformamide (10ml) cooled to 5°C and the mixture was stirred under an argon atmosphere for 30 minutes. 3-Trifluoromethyl-4-fluorobenzyl chloride (280mg) was added and the mixture was allowed to warm to room temperature and then stirred for 4 hours. The reaction mixture was partitioned between ethyl acetate and water. The organic extracts were washed with water, dried (MgSO₄), concentrated in vacuo and purified by flash column chromatography, using iso-hexane followed by 5% ethyl acetate/iso-hexane as eluent, to give the desired product (140mg, 34%). ¹H NMR (CDCl₃) δ 3.9 (s, 3H), 5.15 (s, 2H), 5.75 (s, 2H), 6.9-7.2 (m, 4H), 7.3-7.5 (m, 7H); m/z 476 (M+H⁺)

In a similar manner but using the appropriate indole and benzyl halide was prepared:-

15 Ethyl-N-(3-trifluoromethyl-4-chlorobenzyl)-4-chloro-5-methoxyindole-2-carboxylate
82% yield. NMR (CDCl₃) δ 1.4 (t, 3H), 3.95 (s, 3H), 4.35 (q, 2H), 5.8 (s, 2H), 7.0-7.2 (m, 3H), 7.3-7.5 (m, 3H).

20 (v) Methyl-N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylate

A mixture of methyl-N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-benzyloxyindole-2-carboxylate (140mg) and 5% Pd/C (50mg) in ethyl acetate (10ml) was stirred under a hydrogen atmosphere for 5 hours, filtered through celite, concentrated in vacuo and purified by flash column chromatography using a gradient of 10-25% ethyl acetate/iso-hexane as eluent to give the desired product (60mg, 53%). ¹H NMR (CDCl₃) δ 3.9 (s, 3H), 4.9 (d, 1H), 5.8 (s, 2H), 6.9-7.2 (m, 4H), 7.4 (m, 2H); m/z 384 (M-H⁺)

In a similar manner but using the appropriate benzyl halide was prepared:

Methyl-N-(3-trifluoromethyl-4-chlorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylate
30 89% yield. NMR (CD₃SOCD₃) δ 3.80 (s, 3H), 5.92 (s, 2H), 7.05 (t, 1H), 7.11 (dd, 1H), 7.22 (m, 2H), 7.60 (m, 2H), 9.37 (s, 1H); m/z 401 (MH⁺).

In a similar manner but starting from 2,4-difluoro-3-hydroxybenzaldehyde was prepared

Ethyl N-(3-trifluoromethyl-4-fluorobenzyl)-4,6-difluoro-5-hydroxyindole-2-carboxylate

- 32 -

¹H NMR (CD₃SOCD₃) δ 3.80 (s, 3H), 5.80 (s, 2H), 7.20-7.60 (m, 5H), 9.70 (s, 1H); m/z 402.2 (M-H⁺)

Ethyl-N-(3-trifluoromethyl-4-chlorobenzyl)-4-chloro-5-hydroxyindole-2-carboxylate was prepared from ethyl-N-(3-trifluoromethyl-4-chlorobenzyl)-4-chloro-5-methoxyindole-2-carboxylate by using the method as described in E(iv). 42% yield. ¹H NMR (CD₃SOCD₃) δ 1.39 (t, 3H), 4.32 (q, 2H), 5.37 (s, 1H), 5.79 (s, 2H), 6.99-7.11 (m, 3H), 7.31-7.39 (m, 2H), 7.47 (d, 1H); m/z 430, 432 (M-H⁺)

Method C

10 Ethyl 5-acetoxy-3-bromoindole-2-carboxylate

N-Bromosuccinimide (0.14 g) was added to a stirred solution of ethyl 5-acetoxyindole-2-carboxylate (0.2 g) in DMF (3.0 ml). The reaction was stirred for 4 hours, then poured into water. The resulting precipitate was filtered and dried *in vacuo* to give the title compound as a white powder (0.23 g, 87%). NMR 1.38 (t, 3H), 2.23 (s, 3H), 4.38 (q, 2H), 7.10 (dd, 1H), 7.23 (d, 1H), 7.50 (d, 1H), 12.28 (bs, 1H); m/z 326 (M⁺).

Method C2

Ethyl 5-acetoxy-3-chloroindole-2-carboxylate

A solution of ethyl 5-acetoxyindole-2-carboxylate (500mg) in dichloromethane (10ml) was stirred at room temperature in the presence of N-chlorosuccinimide (297mg) and potassium carbonate (279mg) overnight. The resulting precipitate was collected by filtration, washed with cold dichloromethane followed by water and dried under vacuum overnight to give the desired product as a white powder (425mg, 75%). NMR: 1.35 (t,3H), 2.25 (s,3H), 4.4 (q,2H), 7.1 (d,1H), 7.3 (s,1H), 7.5 (d,1H), 12.2 (s,1H); m/z 281.9 (MH⁺).

Method C 3

15 Ethyl 5-acetoxy-3-iodoindole-2-carboxylate

A solution of ethyl 5-acetoxyindole-2-carboxylate (1g) in dimethylformamide (2ml) was stirred at room temperature in the presence of potassium carbonate (1.12g) and iodine (1.029g) for 18 hours. The reaction was diluted with water (30ml) and the resulting solid was filtered, washed with water and dried to give the desired product 1.32g, 87%). NMR: δ (CD₃SOCD₃) 1.4 (t, 3H), 4.4 (q,2H), 7.1 (d,1H), 7.15 (s,1H), 7.45 (d,1H), 12.3 (s,1H); m/z 372(M-H)

Ethyl N-(3-fluoro-4-trifluoromethylbenzyl)-5-acetoxy-3-iodoindole-2-carboxylate

To a solution of ethyl 5-acetoxy-3-iodoindole-2-carboxylate (400mg) in dimethylformamide (15ml) was added potassium carbonate (340mg), tetrabutyl ammonium iodide (10mg) and 4-fluoro-3-trifluoromethylbenzyl bromide (330mg). The mixture was stirred for 18 hours. The mixture was diluted with water (10ml) and extracted with ethyl acetate. The organic
 5 extracts were dried, concentrated and purified by column chromatography using 5% ethyl acetate/*iso*-hexane as the eluant to give the desired product (520mg, 89%). NMR (CD₃SOCD₃): δ 1.3 (t, 3H), 2.25 (s, 3H), 4.3 (q, 2H), 5.85 (s, 2H), 7.2 (m, 3H), 7.4 (m, 1H), 7.8 (m, 2H); m/z 550 (MH⁺)

- 10 In a similar manner but using the appropriate ethyl 5-acetoxy-3-haloindole-2-carboxylate and benzyl halide were prepared :-

Ethyl N-(3-fluoro 4-trifluoromethylbenzyl)-5-acetoxy-3-chloroindole-2-carboxylate

70% yield. 458.1 (MH⁺)

Ethyl N-(3-trifluoromethyl-4-fluorobenzyl)-5-acetoxy-3-bromoindole-2-carboxylate

- 15 96% yield. NMR (CDCl₃) δ 1.4 (t, 3H), 2.3 (s, 3H), 4.4 (q, 2H), 5.75 (s, 2H), 7.0-7.2 (m, 3H), 7.3 (m, 1H), 7.4 (m, 2H); m/z 502/504 (MH⁺).

Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxy-3-bromoindole-2-carboxylate

79% yield. NMR (CDCl₃) δ 1.4 (t, 3H), 2.35 (s, 3H), 4.4 (q, 2H), 5.8 (s, 2H), 7.05 (d, 1H), 7.1 (dd, 1H), 7.3 (m, 1H), 7.4 (d, 1H), 7.5 (m, 1H), 7.6 (s, 1H); m/z 518/520 (MH⁺)

- 20 Ethyl N-(3-chloro-4-trifluoromethylbenzyl)-5-acetoxy-3-bromoindole-2-carboxylate

63% yield. NMR (CDCl₃) δ 1.4 (t, 3H), 2.35 (s, 3H), 4.4 (q, 2H), 5.8 (s, 2H), 6.95 (d, 1H), 7.1 (dd, 1H), 7.25 (m, 2H), 7.5 (m, 1H), 7.6 (d, 1H); m/z 518/520 (MH⁺).

Method D

- 25 Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-3-methoxy-5-hydroxyindole-2-carboxylate

(i) Ethyl 5-acetoxyindole-2-carboxylate

- A mixture of ethyl 3-benzyloxyindole-2-carboxylate (10g), cyclohexene (50ml) and 10% palladium on carbon (2g) in ethyl acetate (500ml) was refluxed for 4 hours. The mixture was cooled and filtered through Celite. Acetic anhydride (5ml) and N-dimethylaminopyridine (0.1g) was added and
 30 the mixture was refluxed for 15 mins. The mixture was cooled and ethanol was added to destroy excess acetic anhydride. The mixture was concentrated and the residue was recrystallised from ethyl acetate/*iso*-hexane to give the desired product as white needles (6.44g, 77%) NMR

(CD₃SOCD₃) δ 1.33 (t, 3H), 2.23 (s, 3H), 4.32 (q, 2H), 7.0 (dd, 1H), 7.13 (s, 1H), 7.38 (d, 1H), 7.42 (d, 1H), 11.93 (bs, 1H); m/z (M-H⁺)

(ii) Ethyl 5-acetoxy diazoindole-2-carboxylate

- 5 To a solution of ethyl 5-acetoxyindole-2-carboxylate (5g) was added sodium nitrite (20g) followed dropwise by glacial acetic acid (20ml). After about half addition, brown fumes were evolved. The mixture was cooled to -10°C and the remainder of the acetic acid was added. The mixture was allowed to stir for 18 hours. A further amount of sodium nitrite (10g) and acetic acid (10ml) was added and the resulting mixture was stirred for 18 hours. The mixture was partitioned between
10 ethyl acetate and water. The organic extracts were separated, dried and concentrated to low volume. Hexane was added and the resulting solid was filtered to give the desired product (5.2g, 94%).
NMR (CDCl₃) δ 0.8 (t, 3H), 4.5 (q, 2H), 7.1 (dd, 1H), 7.4 (d, 1H), 8.0 (d, 1H); m/z 273 (M+H⁺)

(iii) Ethyl 3-methoxy-5-acetoxyindole-2-carboxylate

- 15 To a solution of ethyl 5-acetoxy diazoindole-2-carboxylate (4.6g) in 1,2-dichloroethane was added methanol (10ml), followed by a catalytic amount of rhodium (II) acetate dimer and the resulting mixture was refluxed for 18 hours. The mixture was concentrated and the resulting residue was purified by column chromatography using 20% ethyl acetate / isohexane as eluent to give the desired product, which was purified further by titration with diethyl ether (2.34g, 50%). NMR
20 (CDCl₃) δ 1.4 (t, 3H), 2.3 (s, 3H), 4.05 (s, 3H), 4.4 (q, 2H), 7.05 (dd, 1H), 7.2-7.25 (m, 2H), 7.45 (d, 1H), 8.4 (bs, 1H); m/z 278.4 (M+H⁺).

Method E

Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylate

- 25 (i) Ethyl 2-acetyl-2-(N³-(3-chloro-4-methoxyphenyl)hydrazino) propionate
Ethereal HCl (60 ml) was added to a solution of 3-chloro-p-anisidine in ethyl acetate (300ml) to precipitate the salt, which was isolated by filtration and air dried. The salt (18.5 g) was suspended in 1.5 N HCl (230 ml) at -5°C under argon. A solution of sodium nitrite (6.9 g) in water (50 ml) was added over 15 minutes to form a solution/slurry, which was stirred at -5°C
30 for a further 1 hour. (solution A)

A solution of sodium hydroxide (5.36 g) in water (10 ml) was added to a solution of ethyl-2-methylacetoacetate (13.5 ml) in ethanol (80 ml) at 5°C. The reaction was stirred at 5°C for a further 1 hour and the pH was then adjusted to 4 by addition of sodium acetate (20 g). (solution B)

5

Solution B was added to solution A at -5°C and the mixture was allowed to warm to ambient temperature over 3 hours before partitioning between water (250 ml) and ethylacetate (250 ml). The organic phase was dried (MgSO₄), concentrated under vacuo and purified by column chromatography using 15% ethylacetate / isohexane as the eluant to yield the desired product

10 (7 g, 21%); NMR (CDCl₃) δ 1.24 (t, 3H), 1.63 (s, 3H), 2.34 (s, 3H), 3.98 (s, 3H), 4.22-4.35 (m, 2H), 7.02 (d, 1H), 7.72 (dd, 1H), 7.83 (d, 1H) m/z 270 (M-CH₃COH)⁺

In a similar manner but starting from 3-fluoro-4-methoxyaniline was prepared:

Ethyl 2-acetyl-2-(N'-(3-fluoro-4-methoxyphenyl)hydrazino) propionate

15 NMR (CD₃SOCD₃) δ 1.25 (t, 3H), 1.55 (s, 3H), 2.35 (s, 3H), 4.0 (s, 3H), 4.2 (q, 2H), 7.4 (t, 1H), 7.5 (dd, 1H), 7.6 (d, 1H); m/z 255 (MH⁺)

In a similar manner but starting from 3,5-dichloro-4-methoxyaniline was prepared:

Ethyl 2-(N'-(3,5-dichloro-4-methoxyphenyl)hydrazino) propionate

NMR (CDCl₃) δ 1.4 (t, 3H), 2.05 (s, 3H), 3.85 (s, 3H), 4.3 (q, 2H), 7.13 (s, 2H), 7.52 (bs, 1H); m/z 307 (MH⁺)

20 (ii) Ethyl 5-methoxy-6-chloroindole-2-carboxylate

A solution of ethyl 2-acetyl-2-(N'-(3-chloro-4-methoxyphenyl)hydrazino) propionate (1 g) and p-toluenesulphonic acid (1 g) in toluene (30 ml) was stirred at 100°C for 18 hours. The mixture was then concentrated and purified by column chromatography using 15% ethylacetate / isohexane as the eluant to yield the desired product (70 mg, 8%); NMR (CDCl₃)

25 δ 1.42 (t, 3H), 3.95 (s, 3H), 4.42 (q, 2H), 7.11 (s, 2H), 7.46 (s, 1H), 8.86 (bs, 1H)

In a similar manner but starting from ethyl 2-acetyl-2-(N'-(3-fluoro-4-methoxyphenyl) hydrazino) propionate was prepared :

Ethyl 5-methoxy-6-fluoroindole-2-carboxylate NMR (CD₃SOCD₃) δ 1.3 (t, 3H), 3.8 (s, 3H), 4.3 (q, 2H), 7.1 (s, 1H), 7.2 (d, 1H), 7.3 (d, 1H); m/z 237 (MH⁺)

30 In a similar manner by starting from ethyl 2-(N'-(3,5-dichloro-4-methoxyphenyl) hydrazino) propionate was prepared :

Ethyl 5-methoxy-4,6-dichloroindole-2-carboxylate NMR (CD₃SOCD₃) δ 1.38 (t, 3H), 2.08 (s, 3H), 3.84 (s, 3H), 4.31 (q, 2H), 7.23 (s, 2H), 7.5 (bs, 1H); m/z 307 (MH⁺)

(iii) Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-methoxy-6-chloroindole-2-carboxylate

Ethyl 5-methoxy-6-chloroindole-2-carboxylate was alkylated with 3-trifluoromethyl-4-

- 5 chlorobenzyl bromide using the methodology described in Method A(iii) to give the desired product (650 mg, 64%); NMR (CDCl₃) δ 1.36 (t, 3H), 3.93 (q, 2H), 5.75 (s, 2H), 7.01 (dd, 1H), 7.13 (s, 1H), 7.29 (s, 1H), 7.31 (s, 1H), 7.35 (d, 1H), 7.43 (d, 1H)

In a similar manner using the appropriate indole and benzyl halide were prepared:

10 Ethyl N-(3-trifluoromethyl-4-fluorobenzyl)-5-methoxy-6-chloroindole-2-carboxylate

NMR (CD₃SOCD₃) δ 1.25 (t, 3H), 3.9 (s, 3H), 4.3 (q, 2H), 5.85 (s, 2H), 7.1-7.4 (m, 4H), 7.55 (d, 1H), 7.9 (s, 1H).

Ethyl N-(3,4-dichlorobenzyl)-5-methoxy-6-fluoroindole-2-carboxylate

- NMR (CD₃SOCD₃) δ 1.25 (t, 3H), 3.8 (s, 3H), 4.2 (q, 2H), 5.75 (s, 2H), 6.9 (d, 1H), 7.3-7.4
15 (m, 3H), 7.5 (d, 1H), 7.6 (d, 1H)

Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-methoxy-6-fluoroindole-2-carboxylate

NMR (CD₃SOCD₃) δ 1.36 (t, 3H), 3.92 (s, 3H), 4.31 (q, 2H), 5.72 (s, 2H), 6.95-7.05 (m, 2H), 7.15 (d, 1H), 7.3 (s, 1H), 7.36 (d, 1H), 7.43 (s, 1H).

Ethyl N-(3,4-dichlorobenzyl)-5-methoxy-4,6-dichloroindole-2-carboxylate

- 20 NMR (CDCl₃) δ 1.39 (t, 3H), 3.91 (s, 3H), 4.33 (q, 2H), 5.7 (s, 2H), 6.82 (dd, 1H), 7.11 (d, 1H), 7.24 (s, 1H), 7.34 (d, 1H), 7.42 (s, 1H)

Ethyl N-(3-trifluoromethyl-4-dichlorobenzyl)-5-methoxy-4,6-dichloroindole-2-carboxylate

NMR (CDCl₃) δ 1.4 (t, 3H), 3.95 (s, 3H), 4.35 (q, 2H), 5.75 (s, 2H), 7.0 9d, 1H), 7.25-7.5 (m, 4H).

25 Ethyl N-(3,4-dichlorobenzyl)-5-methoxy-6-chloroindole-2-carboxylate

NMR (CDCl₃) δ 1.36 (t, 3H), 3.94 (s, 3H), 4.31 (q, 2H), 5.69 (s, 2H), 6.82 (dd, 1H), 7.09 (d, 1H), 7.14 (s, 1H), 7.24-7.35 (m, 3H); m/z 414 (MH⁺)

(iv) Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylate

A mixture of ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-methoxy-6-chloroindole-2-

- 30 carboxylate (650 mgs) and trimethylsilyliodide (0.8 ml) in chloroform (50 ml) was stirred at 50°C for 18 hours. Further aliquots of trimethylsilyliodide were added until no starting material remained and the reaction was then poured into methanol (100 ml). The mixture was

concentrated under vacuo and purified by column chromatography using 15% ethyl acetate / isohexane as the eluant to yield the desired product as a white solid (276 mg, 44%); NMR (CDCl₃) δ 1.36 (t, 3H), 4.31 (q, 2H), 5.75 (s, 2H), 7.0 (dd, 1H), 7.24-7.51 (m, 3H), 7.38 (d, 1H), 7.44 (d, 1H)

5

In a similar manner, but using ethyl N-(3-trifluoromethyl-4-fluorobenzyl)-5-methoxy-6-chloroindole-2-carboxylate or ethyl N-(3,4-dichlorobenzyl)-5-methoxy-6-fluoroindole-2-carboxylate or ethyl N-(3,4-dichlorobenzyl)-5-methoxy-4,6-dichloroindole-2-carboxylate or ethyl N-(3,4-dichlorobenzyl)-5-methoxy-6-chloroindole-2-carboxylate or ethyl N-(3-

10 trifluoromethyl-4-chlorobenzyl)-5-methoxy-6-fluoroindole-2-carboxylate or ethyl N-(3-trifluoromethyl-4-dichlorobenzyl)-5-methoxy-4,6-dichloroindole-2-carboxylate

were prepared:

Ethyl N-(3-trifluoromethyl-4-fluorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylate

53% yield. NMR (CD₃SOCD₃) δ 1.25 (t, 3H), 4.25 (q, 2H), 5.85 (s, 2H), 7.1-7.25 (m, 3H), 7.4

15 (t, 1H), 7.5 (d, 1H), 7.8 (s, 1H), 9.8 (s, 1H); m/z 414 (M-H⁺)

Ethyl N-(3,4-dichlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylate

31% yield. NMR (CDCl₃) δ 1.4 (t, 3H), 4.3 (q, 2H), 5.7 (s, 2H), 6.8 (dd, 1H), 7.0 (d, 1H), 7.1-7.3 (m, 2H); m/z 380 (M-H⁺)

Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylate

20 26% yield. NMR (CDCl₃) δ 1.35 (t, 3H), 4.31 (q, 2H), 4.98 (bd, 1H), 5.72 (s, 2H), 6.96 (d, 1H), 7.01 (dd, 1H), 7.23-7.3 (m, 2H), 7.37 (d, 1H), 7.44 (s, 1H); m/z 414, 416 (M-H⁺).

Ethyl N-(3,4-dichlorobenzyl)-5-hydroxy-4,6-dichloroindole-2-carboxylate

69% yield. NMR (CDCl₃) δ 1.39 (t, 3H), 4.34 (q, 2H), 5.65 (bs, 1H), 7.7 (s, 2H), 6.82 (dd, 1H), 7.1 (d, 1H), 7.23 (s, 1H), 7.33 (d, 1H), 7.35 (s, 1H); m/z 436, 434, 432, 430 (M-H⁺)

25 Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-4,6-dichloroindole-2-carboxylate

80% yield. NMR (CDCl₃) δ 1.39 (t, 3H), 4.36 (q, 2H), 5.66 (s, 1H), 5.75 (s, 2H), 7.0 (dd, 1H), 7.12 (s, 1H), 7.35-7.41 (m, 2H), 7.43 (d, 1H); 466, 468 (M-H⁺)

Ethyl N-(3,4-dichlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylate

37% yield. m/z 398 (M-H⁺)

30

Method E2Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxy-6-bromoindole-2-carboxylate(i) Ethyl-5-methoxy-6-bromoindole-2-carboxylate

The procedure described in method E(i)-(ii) was repeated using 3-bromo-4-methoxy aniline to give the desired product (24% yield): ¹H NMR (DMSO-d₆) δ1.30 (t, 3H), 3.80 (s, 3H), 4.30 (q, 2H), 7.05 (m, 1H), 7.25 (s, 1H), 7.60 (s, 1H), 11.79 (s, 1H); m/z 296.3 (M-H⁺).

(ii) Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxy-6-bromoindole-2-carboxylate

The procedure described in method A(i)-(iii) was repeated using the appropriate benzyl halide to give the desired product : ¹H NMR (DMSO-d₆) δ1.22 (t, 3H), 2.32 (s, 3H), 4.25 (q, 2H), 5.90 (s, 2H), 7.10 (m, 1H), 7.40 (s, 1H), 7.60 (d, 1H), 7.63 (s, 1H), 7.68 (m, 1H), 8.10(s, 1H)

In a similar manner but using 3,4-dichlorobenzyl chloride was prepared :

Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxy-6-bromoindole-2-carboxylate

m/z 486.2 (M-H⁺)

Method E315 Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-7-fluoroindole-2-carboxylate(i) Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-benzyloxy-7 fluoroindole-2-carboxylate

The procedure described in Method E(i)-(iii) was repeated using 2-fluoro-4-benzyloxy aniline as starting material to give the desired product (71% yield): ¹H NMR (DMSO-d₆) δ1.22(t, 3H), 4.25(q, 2H), 5.10(s, 2H), 5.90(s, 2H), 6.95(m, 1H), 7.15(m, 2H), 7.30-7.50(m, 6H), 7.60(m, 2H)

(ii) Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-7 fluoroindole-2-carboxylate

To a solution of Ethyl N-(3-trifluoromethyl-4-chlorobenzyl)-5-benzyloxy-7 fluoroindole-2-carboxylate (50mgs) in ethyl acetate (5ml) was added a catalytic amount of 5% palladium on carbon and the resulting was stirred under a hydrogen atmosphere for 72 hours.

25 The mixture was filtered and concentrated in vacuo to give the desired product (59mg): m/z 414.25 (M-H⁺)

Example 27**Pharmaceutical Compositions**

This Example illustrates, but is not intended to limit, representative pharmaceutical dosage forms of the invention as defined herein (the active ingredient being termed "Compound X"), for therapeutic or prophylactic use in humans:

- 39 -

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X.	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

5

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

- 40 -

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur	488.5
Magnesium	1.5

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	to adjust pH to 7.6
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

5 (f)

<u>Injection II</u>	<u>(10 mg/ml)</u>
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%

(g)

<u>Injection III</u>	<u>(1mg/ml, buffered to pH6)</u>
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%

- 41 -

(h)

<u>Aerosol I</u>	<u>mg/ml</u>
Compound X	10.0
Sorbitan trioleate	13.5
Trichlorofluoromethane	910.0
Dichlorodifluoromethane	490.0

(i)

<u>Aerosol II</u>	<u>mg/ml</u>
Compound X	0.2
Sorbitan trioleate	0.27
Trichlorofluoromethane	70.0
Dichlorodifluoromethane	280.0
Dichlorotetrafluoroethane	1094.0

5 (j)

<u>Aerosol III</u>	<u>mg/ml</u>
Compound X	2.5
Sorbitan trioleate	3.38
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

(k)

<u>Aerosol IV</u>	<u>mg/ml</u>
Compound X	2.5
Soya lecithin	2.7
Trichlorofluoromethane	67.5
Dichlorodifluoromethane	1086.0
Dichlorotetrafluoroethane	191.6

- 42 -

(l)

<u>Ointment</u>	<u>ml</u>
Compound X	40 mg
Ethanol	300 µl
Water	300 µl
1-Dodecylazacycloheptan-2-one	50 µl
Propylene glycol	to 1 ml

Note:

Compound X in the above formulations may comprise a compound as illustrated in Examples herein.

- 5 The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate. The aerosol formulations (h)-(k) may be used in conjunction with standard, metered dose aerosol dispensers, and the suspending agents sorbitan trioleate and soya lecithin may be replaced by an alternative
- 10 suspending agent such as sorbitan monooleate, sorbitan sesquioleate, polysorbate 80, polyglycerol oleate or oleic acid.

15


20

25

CLAIMS

1. A compound of the formula (I):

5



(I)


wherein:

- R¹ is hydrogen, halo or methoxy;
- 10 R² is hydrogen, halo, methyl, ethyl or methoxy;
- R³ is a halo group or a trifluoromethyl group;
- R⁴ is a halo group or a trifluoromethyl group;
- R⁵ is hydrogen or halo;
- R⁶ is hydrogen or halo;
- 15 provided that when R⁵ and R⁶ are both hydrogen, and one of R³ or R⁴ is chloro or fluoro, then the other is not chloro or fluoro;
- or a pharmaceutically acceptable salt or prodrug thereof.
2. A compound according to claim 1, wherein in the formula (I):
- 20 R¹ is hydrogen, fluoro or chloro;
- R² is hydrogen, chloro, bromo, iodo or methoxy;
- R³ is fluoro, chloro, bromo, iodo;
- R⁴ is trifluoromethyl;
- R⁵ and R⁶ are hydrogen.

25

- 44 -

3. A compound according to claim 1, wherein in the formula (I):
 R^1 is hydrogen, fluoro or chloro;
 R^2 is hydrogen, chloro, bromo, iodo or methoxy;
 R^3 is trifluoromethyl;
 5 R^4 is fluoro, chloro, bromo or iodo;
 R^5 and R^6 are hydrogen.
4. A compound according to claim 1, wherein in the formula (I):
 R^1 is hydrogen, fluoro or chloro;
 10 R^2 is hydrogen, chloro, bromo, iodo or methoxy;
 R^3 and R^4 are both halo, especially fluoro, chloro or bromo, or one of R^3 and R^4 is chloro and the other one of R^3 and R^4 is fluoro;
 one or both of R^5 and R^6 is halo.
- 15 5. A compound according to claim 1 which is a compound of formula (IA):



(IA)

- wherein R^1 , R^2 and R^4 are as defined in claim 1, or a pharmaceutically acceptable salt or prodrug thereof.
- 20

6. A compound according to claim 1 which is any of the following:
 N -(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid;
 N -(3-fluoro-4-trifluoromethylbenzyl)-5-hydroxyindole-2-carboxylic acid;
 25 N -(3-chloro-4-trifluoromethylbenzyl)-5-hydroxyindole-2-carboxylic acid;
 N -(3-bromo-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid;


- N*-(3-fluoro-4-bromobenzyl)-5-hydroxyindole-2-carboxylic acid;
N-(3-bromo-4-fluorobenzyl)-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-fluorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylic acid
N-(3-trifluoromethyl-4-chlorobenzyl)-4-fluoro-5-hydroxyindole-2-carboxylic acid;
5 *N*-(3-trifluoromethyl-4-fluorobenzyl)-4,6-difluoro-5-hydroxyindole-2-carboxylic acid;
N-(3,4-chlorobenzyl)-4,6-dichloro-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-fluorobenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid;
N-(3-chloro-4-trifluoromethylbenzyl)-3-bromo-5-hydroxyindole-2-carboxylic acid;
10 *N*-(3-fluoro-4-trifluoromethylbenzyl)-3-chloro-5-hydroxyindole-2-carboxylic acid;
N-(3-fluoro-4-trifluoromethylbenzyl)-3-iodo-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-3-methoxy-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-fluorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid;
15 *N*-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-7-fluoroindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-bromoindole-2-carboxylic acid;
N-(3,4-dichlorobenzyl)-5-hydroxy-6-bromoindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylic acid;
N-(3,4-dichlorobenzyl)-5-hydroxy-6-fluoroindole-2-carboxylic acid;
20 *N*-(3,4-dichlorobenzyl)-5-hydroxy-6-chloroindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-4-chloro-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-4,6-dichloro-5-hydroxyindole-2-carboxylic acid;
N-(3-trifluoromethyl-4-chlorobenzyl)-5-acetoxyindole-2-carboxylic acid (prodrug of
N-(3-trifluoromethyl-4-chlorobenzyl)-5-hydroxyindole-2-carboxylic acid).

25

7. A process for preparing a compound according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof, which process comprises:

(a) reacting a compound of formula (II):


- 46 -



(II)

where R^1 , R^2 , R^5 and R^6 are as defined in claim 1, R^a is carboxy or a protected form thereof, and R^b is hydrogen or a suitable hydroxy protecting group, with a compound of formula (III):

5



(III)

where R^3 and R^4 are as defined in claim 1 and L is a displaceable group;
and optionally thereafter:

- 10 (b) (i) converting a resulting compound of the formula (I) into another compound of the formula (I);
 - (ii) removing any protecting groups; or
 - (iii) forming a pharmaceutically acceptable salt or prodrug thereof.
- 15 8. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or prodrug thereof, for use in a method of treatment of the human or animal body by therapy.
9. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable
- 20 salt or prodrug thereof, for use as a medicament.
10. A compound according to claim 9, which is for use as a medicament for antagonising an MCP-1 mediated effect in a warm-blooded animal.

- 47 -

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or prodrug thereof, in association with a pharmaceutically acceptable excipient or carrier.
- 5 12. Use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for use in antagonising an MCP-1 mediated effect in a warm-blooded animal.
13. A method of treating inflammatory disease which comprises administering to a host in
10 need of such treatment a compound according to any one claims 1 to 6 or a pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition according to claim 11.
14. A method of antagonising an MCP-1 mediated effect in a warm-blooded animal in
need of such treatment which comprises administering to said animal an effective amount of a
15 compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition according to claim 11.

20

25

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00069

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D209/42 A61K31/404 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 07351 A (FAULL ALAN WELLINGTON ; ZENECA LTD (GB); BARKER ANDREW JOHN (GB); K) 18 February 1999 (1999-02-18) cited in the application claims 1,8	1-14
P,A	WO 00 46196 A (FAULL ALAN WELLINGTON ; ASTRAZENECA UK LTD (GB); KETTLE JASON GRANT) 10 August 2000 (2000-08-10) the whole document	1-14

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

13 March 2001

Date of mailing of the international search report

28.03.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 apo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schmid, J-C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 01/00069

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int: Application No
PCT/GB 01/00069

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9907351 A	18-02-1999	AU 8638198 A	01-03-1999
		BR 9811818 A	15-08-2000
		CN 1265591 T	06-09-2000
		EP 1003504 A	31-05-2000
		HR 20000061 A	31-12-2000
		NO 20000573 A	04-02-2000
		PL 338948 A	04-12-2000
		ZA 9807090 A	08-02-1999
WO 0046196 A	10-08-2000	AU 2121300 A	25-08-2000

作为 MCP-1 受体拮抗剂的吲哚类衍生物

本发明涉及式 (I) 的化合物或其药学可接受盐或前药, 其中: R^1 是氢、卤素或甲氧基; R^2 是氢、卤素、甲基、乙基或甲氧基; R^3 是卤素或三氟甲基; R^4 是卤素或三氟甲基; R^5 是氢或卤素; R^6 是氢或卤素; 条件是当 R^5 和 R^6 同时为氢, 和 R^3 或 R^4 之一是氯或氟时, 则其它的不是氯或氟。这些化合物对炎症性疾病的治疗具有有效活性, 尤其是拮抗温血动物如人体中的 MCP-1 介导的效应。

